NPPB and coronary artery disorder: Although our study found no significant differences between HTX recipients with ivabradine or metoprolol in coronary artery disease, coronary stenting, or high-sensitivity cardiac troponin T, patients treated with ivabradine had a significantly lower LVEDP and NT-proBNP level—findings that may reflect improved microvascular integrity and changes in cardiac metabolism.